7 risultati
The study will be conducted in compliance with International Standard good clinical practices (GCPs) and the Declaration of Helsinki. The protocol was approved by local Institutional Review Board and registered in clinical trials.gov.
Clinical and Laboratory Evaluation Blood counts and liver
Idiopathic pulmonary fibrosis (IPF) is a progressive and heterogeneous fibrotic lung disease. It is universally fatal, with an average time to death between two to five years.
Patients with IPF experience significantly diminished quality of life and increased symptom burden. Besides dyspnea, cough,
Background:
Pulmonary Sarcoidosis (PS) is defined as a multisystem granulomatous disorder of unknown cause affecting different vital organs, especially the lungs . The pathogenesis is complex and a single immunologic reaction and modulation of one cytokine is unlikely to resolve all aspects of the
Background:
Idiopathic Pulmonary Fibrosis (IPF) is a progressive fibrotic lung disease of unknown cause with a median survival of 3-5 years (Raghu et al. 2011). As the disease progresses, worsening of lung function and gas exchange impairment cause hypoxemia during physical activity leading to a
Chronic cough is one of the most debilitating symptoms in patients with IPF. It is estimated that over 80% of patients with IPF experience clinically significant cough. The impact of chronic cough on QOL includes fatigue, embarrassment, anxiety, sleep disturbance, hoarseness, incontinence,
Subjects will come to our center to be enrolled. Baseline data collection (performance of a six-minute walk test and completion of questionnaires) and randomization to one of two groups--either Rehab or Wait--will take place at the same enrollment visit if time permits. Subjects in either group will